JAG2 (Jagged2) is a 1238 amino acid (aa) single pass type I transmembrane glycoprotein that is the human homolog of the Drosophilia jagged protein.  JAG2 contains an N-terminal signal peptide, a 1054-aa extracellular domain (ECD) with a DSL domain and 16 EGF-like domains, a transmembrane domain (TM), and a 137-aa cytoplasmic tail.   JAG2 is involved in the mediation of Notch signaling.  Human JAG2 is a putative ligand for the receptor notch 1, the latter a human homolog of the Drosophilia jagged receptor NOTCH.  The Notch signaling pathway is an intercellular signaling mechanism that is essential for proper embryonic development and cell fate decisions. JAG2 is one of several ligands that activate Notch and related receptors.  JAG2 may be involved in limb development.  

JAG2 (Jagged2) is a 1238 amino acid (aa) single pass type I transmembrane glycoprotein that is the human homolog of the Drosophilia jagged protein.  JAG2 contains an N-terminal signal peptide, a 1054-aa extracellular domain (ECD) with a DSL domain and 16 EGF-like domains, a transmembrane domain (TM), and a 137-aa cytoplasmic tail.   JAG2 is involved in the mediation of Notch signaling.  Human JAG2 is a putative ligand for the receptor notch 1, the latter a human homolog of the Drosophilia jagged receptor NOTCH.  The Notch signaling pathway is an intercellular signaling mechanism that is essential for proper embryonic development and cell fate decisions. JAG2 is one of several ligands that activate Notch and related receptors.  JAG2 may be involved in limb development.  

 

Product Details

 

Gene Symbol: JAG2; hJ2; SER2; Jagged2

 

NCBI Gene ID: 3714

 

Uniprot Entry: Q9Y219

 

Construct Details: Full length human JAG2 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without a selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. Multiple choices of a stable antibiotic selection marker are available.

 

Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter +/- a selection marker, see the vector map above)

 

Gene Insert Size: 3717 (bp)

 

Gene Insert Sequence:  

ATGCGGGCGCAGGGCCGGGGGCGCCTTCCCCGGCGGCTGCTGCTGCTGCTGGCGCTCTGGGTGCAGGCGG

CGCGGCCCATGGGCTATTTCGAGCTGCAGCTGAGCGCGCTGCGGAACGTGAACGGGGAGCTGCTGAGCGG

CGCCTGCTGTGACGGCGACGGCCGGACAACGCGCGCGGGGGGCTGCGGCCACGACGAGTGCGACACGTAC

GTGCGCGTGTGCCTTAAGGAGTACCAGGCCAAGGTGACGCCCACGGGGCCCTGCAGCTACGGCCACGGCG

CCACGCCCGTGCTGGGCGGCAACTCCTTCTACCTGCCGCCGGCGGGCGCTGCGGGGGACCGAGCGCGGGC

GCGGGCCCGGGCCGGCGGCGACCAGGACCCGGGCCTCGTCGTCATCCCCTTCCAGTTCGCCTGGCCGCGC

TCCTTTACCCTCATCGTGGAGGCCTGGGACTGGGACAACGATACCACCCCGAATGAGGAGCTGCTGATCG

AGCGAGTGTCGCATGCCGGCATGATCAACCCGGAGGACCGCTGGAAGAGCCTGCACTTCAGCGGCCACGT

GGCGCACCTGGAGCTGCAGATCCGCGTGCGCTGCGACGAGAACTACTACAGCGCCACTTGCAACAAGTTC

TGCCGGCCCCGCAACGACTTTTTCGGCCACTACACCTGCGACCAGTACGGCAACAAGGCCTGCATGGACG

GCTGGATGGGCAAGGAGTGCAAGGAAGCTGTGTGTAAACAAGGGTGTAATTTGCTCCACGGGGGATGCAC

CGTGCCTGGGGAGTGCAGGTGCAGCTACGGCTGGCAAGGGAGGTTCTGCGATGAGTGTGTCCCCTACCCC

GGCTGCGTGCATGGCAGTTGTGTGGAGCCCTGGCAGTGCAACTGTGAGACCAACTGGGGCGGCCTGCTCT

GTGACAAAGACCTGAACTACTGTGGCAGCCACCACCCCTGCACCAACGGAGGCACGTGCATCAACGCCGA

GCCTGACCAGTACCGCTGCACCTGCCCTGACGGCTACTCGGGCAGGAACTGTGAGAAGGCTGAGCACGCC

TGCACCTCCAACCCGTGTGCCAACGGGGGCTCTTGCCATGAGGTGCCGTCCGGCTTCGAATGCCACTGCC

CATCGGGCTGGAGCGGGCCCACCTGTGCCCTTGACATCGATGAGTGTGCTTCGAACCCGTGTGCGGCCGG

TGGCACCTGTGTGGACCAGGTGGACGGCTTTGAGTGCATCTGCCCCGAGCAGTGGGTGGGGGCCACCTGC

CAGCTGGACGCCAATGAGTGTGAAGGGAAGCCATGCCTTAACGCTTTTTCTTGCAAAAACCTGATTGGCG

GCTATTACTGTGATTGCATCCCGGGCTGGAAGGGCATCAACTGCCATATCAACGTCAACGACTGTCGCGG

GCAGTGTCAGCATGGGGGCACCTGCAAGGACCTGGTGAACGGGTACCAGTGTGTGTGCCCACGGGGCTTC

GGAGGCCGGCATTGCGAGCTGGAACGAGACGAGTGTGCCAGCAGCCCCTGCCACAGCGGCGGCCTCTGCG

AGGACCTGGCCGACGGCTTCCACTGCCACTGCCCCCAGGGCTTCTCCGGGCCTCTCTGTGAGGTGGATGT

CGACCTTTGTGAGCCAAGCCCCTGCCGGAACGGCGCTCGCTGCTATAACCTGGAGGGTGACTATTACTGC

GCCTGCCCTGATGACTTTGGTGGCAAGAACTGCTCCGTGCCCCGCGAGCCGTGCCCTGGCGGGGCCTGCA

GAGTGATCGATGGCTGCGGGTCAGACGCGGGGCCTGGGATGCCTGGCACAGCAGCCTCCGGCGTGTGTGG

CCCCCATGGACGCTGCGTCAGCCAGCCAGGGGGCAACTTTTCCTGCATCTGTGACAGTGGCTTTACTGGC

ACCTACTGCCATGAGAACATTGACGACTGCCTGGGCCAGCCCTGCCGCAATGGGGGCACATGCATCGATG

AGGTGGACGCCTTCCGCTGCTTCTGCCCCAGCGGCTGGGAGGGCGAGCTCTGCGACACCAATCCCAACGA

CTGCCTTCCCGATCCCTGCCACAGCCGCGGCCGCTGCTACGACCTGGTCAATGACTTCTACTGTGCGTGC

GACGACGGCTGGAAGGGCAAGACCTGCCACTCACGCGAGTTCCAGTGCGATGCCTACACCTGCAGCAACG

GTGGCACCTGCTACGACAGCGGCGACACCTTCCGCTGCGCCTGCCCCCCCGGCTGGAAGGGCAGCACCTG

CGCCGTCGCCAAGAACAGCAGCTGCCTGCCCAACCCCTGTGTGAATGGTGGCACCTGCGTGGGCAGCGGG

GCCTCCTTCTCCTGCATCTGCCGGGACGGCTGGGAGGGTCGTACTTGCACTCACAATACCAACGACTGCA

ACCCTCTGCCTTGCTACAATGGTGGCATCTGTGTTGACGGCGTCAACTGGTTCCGCTGCGAGTGTGCACC

TGGCTTCGCGGGGCCTGACTGCCGCATCAACATCGACGAGTGCCAGTCCTCGCCCTGTGCCTACGGGGCC

ACGTGTGTGGATGAGATCAACGGGTATCGCTGTAGCTGCCCACCCGGCCGAGCCGGCCCCCGGTGCCAGG

AAGTGATCGGGTTCGGGAGATCCTGCTGGTCCCGGGGCACTCCGTTCCCACACGGAAGCTCCTGGGTGGA

AGACTGCAACAGCTGCCGCTGCCTGGATGGCCGCCGTGACTGCAGCAAGGTGTGGTGCGGATGGAAGCCT

TGTCTGCTGGCCGGCCAGCCCGAGGCCCTGAGCGCCCAGTGCCCACTGGGGCAAAGGTGCCTGGAGAAGG

CCCCAGGCCAGTGTCTGCGACCACCCTGTGAGGCCTGGGGGGAGTGCGGCGCAGAAGAGCCACCGAGCAC

CCCCTGCCTGCCACGCTCCGGCCACCTGGACAATAACTGTGCCCGCCTCACCTTGCATTTCAACCGTGAC

CACGTGCCCCAGGGCACCACGGTGGGCGCCATTTGCTCCGGGATCCGCTCCCTGCCAGCCACAAGGGCTG

TGGCACGGGACCGCCTGCTGGTGTTGCTTTGCGACCGGGCGTCCTCGGGGGCCAGTGCTGTGGAGGTGGC

CGTGTCCTTCAGCCCTGCCAGGGACCTGCCTGACAGCAGCCTGATCCAGGGCGCGGCCCACGCCATCGTG

GCCGCCATCACCCAGCGGGGGAACAGCTCACTGCTCCTGGCTGTCACCGAGGTCAAGGTGGAGACGGTTG

TTACGGGCGGCTCTTCCACAGGTCTGCTGGTGCCTGTGCTGTGTGGTGCCTTCAGCGTGCTGTGGCTGGC

GTGCGTGGTCCTGTGCGTGTGGTGGACACGCAAGCGCAGGAAAGAGCGGGAGAGGAGCCGGCTGCCGCGG

GAGGAGAGCGCCAACAACCAGTGGGCCCCGCTCAACCCCATCCGCAACCCCATTGAGCGGCCGGGGGGCC

ACAAGGACGTGCTCTACCAGTGCAAGAACTTCACGCCGCCGCCGCGCAGGGCGGACGAGGCGCTGCCCGG

GCCGGCCGGCCACGCGGCCGTCAGGGAGGATGAGGAGGACGAGGATCTGGGCCGCGGTGAGGAGGACTCC

CTGGAGGCGGAGAAGTTCCTCTCACACAAATTCACCAAAGATCCTGGCCGCTCGCCGGGGAGGCCGGCCC

ACTGGGCCTCAGGCCCCAAAGTGGACAACCGCGCGGTCAGGAGCATCAATGAGGCCCGCTACGCCGGCAA

GGAGTAG

 

Formulation: pre-packaged viral particles in the conditional medium (serum-free) from HEK293 cells (typical titer 10⁶ - 10⁷ IFU/ml)

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

 

Transduction Protocol

 

Pre-packaged lentiviral particles are most advanced gene delivery tools. Each particles contain a fully sequence verified target gene and are psudotyped with the VSV-G glycoprotein, ready for transduction into into a wide range of cell types including hard-to-transfect primary cells and non-dividing cells. They are supplied in 1-mL aliquot(s) of the serum-/antibiotic-free solution suitable for both in vitro and in vivo delivery. They are produced in HEK293 packaging cells with a typical titer of ≥10⁷ IFU/ml using our optimized LentPAK^TM packaging system. The lentiviral particles can be used to transduce subconfluent target cells. Depending on your purpose, you may choose a specific multiplicity of infection (MOI) or test a range of MOIs to determine which gives you the desired results. Transduction can be enhanced by the addition of polybrene, also known as hexadimethrine bromide (typically at 8-10 μg/ml). 

 

Quick Protocol for Transduction

 

Day 1. Seeding Target Cells

For an example, plate target cells in a 10 cm plate at a density of 1 - 5x 10⁵ cells/ml that will produce approximately 60% confluency in 24 hours.

 

Note: other size plates can also be used depending on the nature of your experiment. Adjust the reagent amount according to Table 1

 

Table 1. Seeding Density of Target Cells (1 day prior to transduction)

Vessel Type	Seeding Target Cell#	Volume of Media
10-cm dish	1 – 5 x 106	10 mL
6-well plate	0.3 – 1 x 106	2 mL/well
12-well plate	0.15 – 0.5 x 106	1 mL/well
24-well plate	0.6 – 2 x 105	0.5 mL/well
96-well plate	1 – 4 x 104	0.1 mL/well

  

Day 2. Transduction

Remove the growth media from the dish/plate prepared the day before. Replace with 1/2 volume of culture medium containing desired amount of lentiviral particles (at 2 to 20 MOI).  For example, add 4.5 mL of growth medium and 0.5 mL of Lentiviral particles, or simply add 5 mL of Lentiviral particles (for a low titer viral preparation or a high MOI transduction). Add polybrene directly to the media on the target cells at 8 μg/ml. Mix by gentle swirling.

 

Incubate at 37°C with 5% CO2 for 4 - 24 hours, then replace the transduction medium with right amount of growth medium according to table 1 (for example 10 mL for 10-cm dish). Culture the cells for 48 – 72 hours, and transduced cells are ready for downstream analyses.

 

Note: Adjust volumes accordingly for transduction of other plate types.  For example, add 1 ml of growth medium and lentiviral particle mixture for 6-well plate, 0.5 ml for 12-well and 0.25 mL for 24-well except for 96 well, in which 100 μl should be used. The change of transduction medium is often unnecessary with our pre-packaged lentiviral particles.  Simply culture cells for 3-4 days before analysis. 

 

The virus-containing media can be changed in as short as 4 hours after transduction if toxicity of the lentiviral transduction is a concern. Normally reverse transcription and genome integration of the lentivector takes place within 24-36 hours. With our ready-to-use, prepackaged lentiviral particles, the change of media is often unnecessary. The transduction process can be ongoing for 2 - 6 days without significant impact on cell growth/viability. The transduction process can also be repeated if desired. For a lentivector with a fluorescent reporter (such as GFP), FACS can be used to enrich for cells that express GFP. If it contains a drug selectable marker, follow the protocol for the particular drug. For example, puromycin selection is usually carried out at 1-10 μg/mL, depending on the target cells’ sensitivity

 

 

Important Safety Information

With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

 

Storage

 

The product is shipped at 4°C for immediate use or with dry ice.  Upon receipt, centrifuge the vial briefly before opening.  Store at –80°C or lower and the product is stable for 3 months.  Avoid repeated freeze-thaw cycles.

 

 

The product should be employed in a Biosafety Level 2 tissue culture facility.

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

Additional supporting documents, including product data sheet (PDS), COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.